| Veru is an oncology and urology biopharmaceutical company. Co.'s prostate cancer pipeline includes: VERU-111, which is used for the treatment of men with metastatic castration resistant prostate cancer; VERU-100, a proprietary peptide formulation for androgen deprivation therapies (ADT); and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes caused by ADT in men with prostate cancer. Co.'s breast cancer drug pipeline includes: Enobosarm, which is a selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 metastatic breast cancer. We show 44 historical shares outstanding datapoints in our VERU shares outstanding history coverage, used to compute VERU market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VERU market cap history over the course of time is important for investors
interested in comparing VERU's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VERU versus a peer is one thing; comparing
VERU market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VERU can fluctuate over the course of history.
With this page we aim to empower investors researching VERU by allowing them to research the VERU market cap history.